Outlook Therapeutics, Inc. (OTLK) — Financial statements
Income statement, balance sheet, and cash flow for Outlook Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.76↑564.3% | 0.11↑157.7% | 0.04↓78.4% | 0.20↓21.9% | 0.26 | |
| Gross Profit | 0.66↑677.2% | -0.11↓157.7% | -0.04↑78.4% | -0.20↑21.9% | -0.26 | |
| Operating Expenses | ||||||
| R&D Expenses | 27,180,640↑65082964.0% | 42↑57.9% | 26↓37.5% | 42↑8.7% | 39 | |
| General & Administrative Expenses | 40↑33.4% | 30↑12.2% | 27↑28.6% | 21↑62.4% | 13 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 40↑33.4% | 30↑12.2% | 27↑28.6% | 21↑62.4% | 13 | |
| Other Expenses | -27,180,612 | 0.00 | 0.00↑100.0% | -0.21 | 0.00 | |
| Operating Expenses | 68↓5.6% | 72↑35.0% | 53↓15.5% | 63↑21.5% | 52 | |
| Total Costs & Expenses | 68↓4.5% | 72↑35.0% | 53↓15.8% | 63↑21.9% | 52 | |
| Operating Results | ||||||
| Operating Income | -67↑6.5% | -72↓35.0% | -53↑15.8% | -63↓21.9% | -52 | |
| Depreciation & Amortization | 0.12↑2.8% | 0.11↑157.7% | 0.04↓78.4% | 0.20↓21.9% | 0.26 | |
| EBITDA | -64↑11.8% | -72↓25.7% | -57↑10.8% | -64↓24.9% | -52 | |
| EBIT | -64↑11.8% | -72↓25.8% | -57↑11.1% | -65↓24.8% | -52 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.19↑91.4% | -2↓44.3% | -2↓4.9% | -1↓58.9% | -0.94 | |
| Interest Income | 0.09↓90.1% | 0.91 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.28↓91.0% | 3↑102.4% | 2↑4.9% | 1↑58.8% | 0.94 | |
| Non-Operating Income | -3↓768.7% | 0.50↓88.3% | 4↑188.0% | 1 | 0.00 | |
| Other Income / Expenses | 3↑184.3% | -4↑37.5% | -6↓96.5% | -3↓107.6% | -1 | |
| Income Before Tax | -64↑15.1% | -75↓27.8% | -59↑10.7% | -66↓24.2% | -53 | |
| Income Tax Expense | -2↓55522.5% | 0.00↑0.0% | 0.00↑0.0% | 0.00↑40.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -62↑17.2% | -75↓27.8% | -59↑10.7% | -66↓24.2% | -53 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -62↑17.2% | -75↓27.8% | -59↑10.7% | -66↓24.2% | -53 | |
| Bottom-Line Net Income | -62↑17.2% | -75↓27.8% | -59↑10.7% | -66↓24.2% | -53 | |
| EPS (Basic) | -1.79↑55.9% | -4.06↑14.0% | -4.72↑24.2% | -6.23↑10.5% | -6.96 | |
| EPS (Diluted) | -1.79↑55.9% | -4.06↑14.0% | -4.72↑24.2% | -6.23↑10.5% | -6.96 | |
| Weighted Average Shares | 35↑87.6% | 19↑48.3% | 13↑18.0% | 11↑38.9% | 8 | |
| Weighted Average Diluted Shares | 25↑37.3% | 19↑48.3% | 13↑18.0% | 11↑38.9% | 8 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.